Ribosomal Protein S6 Kinases - Metabolism
Research News and Information

Sunday, November 22, 2009

BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide.

19 Aug 2009 OBJECTIVE: To evaluate the anti-neoplastic activity of BMS-536924, an IGF-1R inhibitor, in epithelial ovarian cancer and its capacity to potentiate the effect of a PARP inhibitor, 3-aminobenzamide. METHODS: OVCAR-3, OVCAR-4, SKOV-3 and TOV-81D cell ... Read more...

mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma.

30 Jul 2009 BACKGROUND: The mammalian target of rapamycin (mTOR) controls cell growth through protein synthesis regulation. It can be activated by protein kinase B (AKT) or through ribosomal S6 kinase (S6K1). In malignant glioma, mTOR inhibitors have ... Read more...

Complex regulation of mammalian target of rapamycin complex 1 in the basomedial hypothalamus by leptin and nutritional status.

21 Jul 2009 The medial basal hypothalamus, including the arcuate nucleus (ARC) and the ventromedial hypothalamic nucleus (VMH), integrates signals of energy status to modulate metabolism and energy balance. Leptin and feeding regulate the mammalian target of ... Read more...

Latest indexed articles for 'Ribosomal Protein S6 Kinases - Metabolism'

These are the very latest articles for this heading:

• BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. 19 Aug 2009
• mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma. 30 Jul 2009
• Complex regulation of mammalian target of rapamycin complex 1 in the basomedial hypothalamus by leptin and nutritional status. 21 Jul 2009
• The effects of amino acids on glucose metabolism of isolated rat skeletal muscle are independent of insulin and the mTOR/S6K pathway. 19 Jul 2009
• Mammalian target of rapamycin is activated in association with myometrial proliferation during pregnancy. 7 Jul 2009
• Evidence that mechanosensors with distinct biomechanical properties allow for specificity in mechanotransduction. 6 Jul 2009
• Mechanism of PDK1-catalyzed Thr-229 phosphorylation of the S6K1 protein kinase. 29 Jun 2009
• mTOR/S6 kinase pathway contributes to astrocyte survival during ischemia. 15 Jun 2009
• The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways. 14 Jun 2009
• Biphasic activation of the mTOR pathway in the gustatory cortex is correlated with and necessary for taste learning. 8 Jun 2009
• Testosterone induces cardiomyocyte hypertrophy through mammalian target of rapamycin complex 1 pathway. 25 May 2009
• HIF-1 modulates dietary restriction-mediated lifespan extension via IRE-1 in Caenorhabditis elegans. 20 May 2009
• Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase. 12 May 2009
• PDK1 signaling in oocytes controls reproductive aging and lifespan by manipulating the survival of primordial follicles. 5 May 2009
• Components of the mitogen-activated protein kinase cascade are activated in hepatic cells by Echinococcus multilocularis metacestode. 5 May 2009
• Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. 5 May 2009
• Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. 29 Apr 2009
• Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. 18 Apr 2009
• Identification of cAMP-dependent kinase as a third in vivo ribosomal protein S6 kinase in pancreatic beta-cells. 14 Apr 2009
• Inhibition of S6K1 accounts partially for the anti-inflammatory effects of the arginase inhibitor L-norvaline. 11 Mar 2009

See a longer list of these articles.

Technical information about 'Ribosomal Protein S6 Kinases'

Definition: A family of protein serine/threonine kinases which act as intracellular signalling intermediates. Ribosomal protein S6 kinases are activated through phosphorylation in response to a variety of HORMONES and INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS. Phosphorylation of RIBOSOMAL PROTEIN S6 by enzymes in this class results in increased expression of 5' TOP MRNAS. Although specific for RIBOSOMAL PROTEIN S6 members of this class of kinases can act on a number of substrates within the cell. The immunosuppressant SIROLIMUS inhibits the activation of ribosomal protein S6 kinases.

Registry Number: EC 2.7.1.37

Descriptor UI: D019893

Alternative terms: Ribosomal Protein S6 Kinases; S6-H4 Kinase; S6 H4 Kinase; Ribosomal Protein S6 Kinase; S6 Kinase;

Related Mesh Headings: Ribosomal Protein S6;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications;

Tree Number: D08.811.913.696.620.682.700.862; D12.644.360.600; D12.776.476.600;

History Note: 2003(1998); use RIBOSOMAL PROTEIN S6 KINASES (NM) 1985-1997